PAPPAS ARTHUR M 4
Accession 0001144204-18-035850
Filed
Jun 25, 8:00 PM ET
Accepted
Jun 26, 4:54 PM ET
Size
19.8 KB
Accession
0001144204-18-035850
Insider Transaction Report
- Conversion
Series B Preferred Stock, par value $0.001 per share
2018-06-25+290,924→ 0 total(indirect: See footnotes)→ Common Stock (290,924 underlying) - Conversion
Common Stock, par value $0.001 per share
2018-06-25+290,924→ 290,924 total(indirect: See footnotes) - Conversion
Series B Preferred Stock, par value $0.001 per share
2018-06-25+23,894→ 0 total(indirect: See footnotes)→ Common Stock (23,894 underlying) - Conversion
Common Stock, par value $0.001 per share
2018-06-25+23,894→ 23,894 total(indirect: See footnotes)
- Conversion
Common Stock, par value $0.001 per share
2018-06-25+23,894→ 23,894 total(indirect: See footnotes) - Conversion
Common Stock, par value $0.001 per share
2018-06-25+290,924→ 290,924 total(indirect: See footnotes) - Conversion
Series B Preferred Stock, par value $0.001 per share
2018-06-25+290,924→ 0 total(indirect: See footnotes)→ Common Stock (290,924 underlying) - Conversion
Series B Preferred Stock, par value $0.001 per share
2018-06-25+23,894→ 0 total(indirect: See footnotes)→ Common Stock (23,894 underlying)
- Conversion
Series B Preferred Stock, par value $0.001 per share
2018-06-25+290,924→ 0 total(indirect: See footnotes)→ Common Stock (290,924 underlying) - Conversion
Common Stock, par value $0.001 per share
2018-06-25+23,894→ 23,894 total(indirect: See footnotes) - Conversion
Series B Preferred Stock, par value $0.001 per share
2018-06-25+23,894→ 0 total(indirect: See footnotes)→ Common Stock (23,894 underlying) - Conversion
Common Stock, par value $0.001 per share
2018-06-25+290,924→ 290,924 total(indirect: See footnotes)
- Conversion
Series B Preferred Stock, par value $0.001 per share
2018-06-25+23,894→ 0 total(indirect: See footnotes)→ Common Stock (23,894 underlying) - Conversion
Common Stock, par value $0.001 per share
2018-06-25+290,924→ 290,924 total(indirect: See footnotes) - Conversion
Common Stock, par value $0.001 per share
2018-06-25+23,894→ 23,894 total(indirect: See footnotes) - Conversion
Series B Preferred Stock, par value $0.001 per share
2018-06-25+290,924→ 0 total(indirect: See footnotes)→ Common Stock (290,924 underlying)
- Conversion
Series B Preferred Stock, par value $0.001 per share
2018-06-25+290,924→ 0 total(indirect: See footnotes)→ Common Stock (290,924 underlying) - Conversion
Series B Preferred Stock, par value $0.001 per share
2018-06-25+23,894→ 0 total(indirect: See footnotes)→ Common Stock (23,894 underlying) - Conversion
Common Stock, par value $0.001 per share
2018-06-25+23,894→ 23,894 total(indirect: See footnotes) - Conversion
Common Stock, par value $0.001 per share
2018-06-25+290,924→ 290,924 total(indirect: See footnotes)
Footnotes (5)
- [F1]The Series B Preferred Stock, par value $0.001 per share, converted into Common Stock, par value $0.001 per share, on a one-for-one basis and had no expiration date.
- [F2]These shares are held of record by A.M. Pappas Life Science Ventures V, LP ("Pappas Ventures").
- [F3]These shares are held of record by PV V CEO Fund, LP ("CEO Fund" and, together with Pappas Ventures, the "Pappas Funds").
- [F4]AMP&A Management V, LLC ("Management V") is the general partner of each of the Pappas Funds and has a management agreement with Pappas Capital, LLC ("Pappas Capital") whereby Pappas Capital's investment committee has sole power to vote or to direct the vote of, and sole power to dispose or to direct the disposition of, all shares owned by the Pappas Funds. Mr. Arthur Pappas is the sole managing member of Pappas Capital. By virtue of their respective relationships with the Pappas Funds, each of Management V, Pappas Capital and Mr. Pappas may be deemed to indirectly beneficially own the shares of which Pappas Ventures and CEO Fund are the record owners. (continue in footnote 5)
- [F5]Each of Management V, Pappas Capital and Mr. Pappas disclaims beneficial ownership of the shares reported herein, except to the extent of its or his respective pecuniary interests therein. This report shall not be deemed an admission that such reporting persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose.
Documents
Issuer
Kezar Life Sciences, Inc.
CIK 0001645666
Related Parties
1- filerCIK 0001189543
Filing Metadata
- Form type
- 4
- Filed
- Jun 25, 8:00 PM ET
- Accepted
- Jun 26, 4:54 PM ET
- Size
- 19.8 KB